Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | Cetuximab + Subasumstat |
Synonyms | |
Therapy Description | |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
Cetuximab | Erbitux | IMC-C225 | EGFR Antibody 60 | Erbitux (cetuximab) is a monoclonal antibody directed against EGFR, which inhibits signal transduction and cell proliferation (PMID: 28695301). Erbitux (cetuximab) is FDA approved for use in head and neck squamous cell carcinoma and KRAS wild-type, EGFR positive colorectal cancer (FDA.gov). |
Subasumstat | TAK981|TAK 981|TAK-981 | Subasumstat (TAK-981) is a small molecule inhibitor of the SUMO-activating enzyme (SAE), which may lead to activation of anti-tumor immune response and inhibition of tumor growth (PMID: 37420267). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT04065555 | Phase I | Avelumab + Subasumstat Cetuximab Cetuximab + Subasumstat Subasumstat Avelumab | Intratumoral Microdosing of TAK-981 in Head and Neck Cancer | Completed | USA | 0 |